Title: FDA, Merck, and Vioxx
Subtitle: putting patient safety first? : hearing before the Committee on Finance, United States Senate, One Hundred Eighth Congress, second session, November 18, 2004
Subjects: Merck & Co, Drug monitoring, Rofecoxib, Testing, Corrupt practices, Drugs
Places: United States